H.R. 3162

119th Congress

In Committee

Affordable and Safe Prescription Drug Importation Act of 2025

Sponsored byDemocrat:Rep. Schakowsky, Janice D. [D-IL-9]IL· Introduced 1 mai 2025

6

Cosponsors

3

Actions

0

Amendments

1

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the House Committee on Energy and Commerce.

1 mai 2025·1 year ago

Summary

Introduced in House · Updated 3 avril 2026

Affordable and Safe Prescription Drug Importation Act of 2025

This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported.

Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs.

The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements.

The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin.

Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS.

Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.

Timeline

3 actions

  1. Referred to the House Committee on Energy and Commerce.

    1 mai 2025 · IntroReferral

  2. Introduced in House

    1 mai 2025 · IntroReferral

  3. Introduced in House

    1 mai 2025 · IntroReferral

Sponsorship

6 cosponsors

Cosponsors

  • Democrat6100%

Classification

Policy area

Health

Committees

1

  • Energy and Commerce Committee

    House · Standing

    • Referred To1 May 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 5 on 1 mai 2025 to 6 on 22 juillet 2026.

Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.